Cardiovascular responses to microinjection of ATP into the nucleus tractus solitarii of awake rats

Am J Physiol Regul Integr Comp Physiol. 2004 Nov;287(5):R1164-71. doi: 10.1152/ajpregu.00722.2003. Epub 2004 Jul 1.

Abstract

Microinjection of increasing doses of ATP (0.31, 0.62, 1.25, and 2.5 nmol/50 nl) into the nucleus tractus solitarii (NTS) produced a dose-dependent pressor response. Prazosin abolished the pressor response and produced no change in the bradycardic response to ATP. Microinjection of pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid (0.25 nmol/50 nl), a nonselective P2 receptor antagonist into the NTS, reduced the bradycardic response but had no effect on the pressor response to microinjection of ATP (1.25 nmol/50 nl) into the NTS. Microinjection of suramin (2 nmol/50 nl), another nonselective P2 receptor antagonist, had no effect on the pressor and bradycardic responses to microinjection of ATP (1.25 nmol/50 nl) into the NTS. Antagonism of A1 receptors of adenosine with 1,3-dipropyl-8-cyclopentylxanthine also produced no changes in the cardiovascular responses to microinjection of ATP into the NTS. The involvement of excitatory amino acid (EAA) receptors in the pressor and bradycardic responses to microinjection of ATP into the NTS was also evaluated. Microinjection of kynurenic acid, a nonselective EAA receptor antagonist (10 nmol/50 nl), into the NTS reduced the bradycardic response and had no effect on the pressor response to microinjection of ATP into the NTS. The data show that 1) microinjection of ATP into the NTS of awake rats produced pressor and bradycardic responses by independent mechanisms, 2) the activation of parasympathetic component may involve an interaction of P2 and EAA receptors in the NTS, and 3) the sympathoexcitatory response to microinjection of ATP into the NTS was not affected by the blockade of P2, A1, or EAA receptors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine A1 Receptor Antagonists
  • Adenosine Triphosphate / administration & dosage
  • Adenosine Triphosphate / pharmacology*
  • Adrenergic alpha-Antagonists / administration & dosage
  • Adrenergic alpha-Antagonists / pharmacology
  • Animals
  • Atropine Derivatives / pharmacology
  • Autonomic Nervous System / drug effects
  • Blood Pressure / drug effects
  • Dose-Response Relationship, Drug
  • Excitatory Amino Acid Antagonists / administration & dosage
  • Excitatory Amino Acid Antagonists / pharmacology
  • Heart Rate / drug effects
  • Hemodynamics / drug effects*
  • Kynurenic Acid / administration & dosage
  • Kynurenic Acid / pharmacology
  • Male
  • Microinjections
  • Prazosin / administration & dosage
  • Prazosin / pharmacology
  • Purinergic P2 Receptor Antagonists
  • Pyridoxal Phosphate / administration & dosage
  • Pyridoxal Phosphate / analogs & derivatives*
  • Pyridoxal Phosphate / pharmacology
  • Rats
  • Rats, Wistar
  • Solitary Nucleus / anatomy & histology
  • Solitary Nucleus / physiology*
  • Suramin / administration & dosage
  • Suramin / pharmacology
  • Xanthines / administration & dosage
  • Xanthines / pharmacology

Substances

  • Adenosine A1 Receptor Antagonists
  • Adrenergic alpha-Antagonists
  • Atropine Derivatives
  • Excitatory Amino Acid Antagonists
  • Purinergic P2 Receptor Antagonists
  • Xanthines
  • pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid
  • Pyridoxal Phosphate
  • Suramin
  • methylatropine
  • Adenosine Triphosphate
  • 1,3-dipropyl-8-cyclopentylxanthine
  • Kynurenic Acid
  • Prazosin